Morgan Stanley Blueprint Medicines Corp Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Morgan Stanley holds 1,031,170 shares of BPMC stock, worth $133 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,031,170

Previous 568,699 81.32%

Holding current value

$133 Million

Previous $50.3 Million 162.59%

% of portfolio

0.01%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$79.22 - $128.4 $36.6 Million - $59.4 Million	462,471 Added 81.32%	1,031,170 $132 Million
Q1 2025 May 15, 2025	BUY	$86.69 - $115.63 $5.58 Million - $7.44 Million	64,356 Added 12.76%	568,699 $50.3 Million
Q4 2024 Feb 14, 2025	SELL	$82.48 - $101.39 $2.64 Million - $3.25 Million	-32,019 Reduced 5.97%	504,343 $44 Million
Q3 2024 May 14, 2025	BUY	$84.1 - $120.5 $9.68 Million - $13.9 Million	115,103 Added 27.32%	536,362 $49.6 Million
Q3 2024 Nov 14, 2024	BUY	$84.1 - $120.5 $9.68 Million - $13.9 Million	115,103 Added 27.32%	536,362 $49.6 Million
Q2 2024 May 14, 2025	SELL	$85.18 - $108.78 $7.08 Million - $9.04 Million	-83,084 Reduced 16.47%	421,259 $45.4 Million
Q2 2024 Oct 17, 2024	SELL	$85.18 - $108.78 $54.3 Million - $69.3 Million	-637,430 Reduced 60.21%	421,259 $45.4 Million
Q2 2024 Aug 14, 2024	SELL	$85.18 - $108.78 $54.3 Million - $69.3 Million	-637,430 Reduced 60.21%	421,259 $45.4 Million
Q1 2024 Oct 17, 2024	BUY	$73.17 - $99.79 $46.6 Million - $63.6 Million	637,430 Added 151.32%	1,058,689 $100 Million
Q1 2024 Aug 16, 2024	SELL	$73.17 - $99.79 $7.99 Million - $10.9 Million	-109,186 Reduced 9.35%	1,058,689 $100 Million
Q1 2024 May 15, 2024	SELL	$73.17 - $99.79 $7.99 Million - $10.9 Million	-109,186 Reduced 9.35%	1,058,689 $100 Million
Q4 2023 Aug 16, 2024	BUY	$43.96 - $92.84 $32.8 Million - $69.3 Million	746,616 Added 177.23%	1,167,875 $108 Million
Q4 2023 Feb 13, 2024	BUY	$43.96 - $92.84 $35.2 Million - $74.4 Million	801,042 Added 218.37%	1,167,875 $108 Million
Q3 2023 Nov 15, 2023	SELL	$46.9 - $66.0 $1.06 Million - $1.5 Million	-22,663 Reduced 5.82%	366,833 $18.4 Million
Q2 2023 Aug 14, 2023	SELL	$42.2 - $66.37 $6.03 Million - $9.48 Million	-142,831 Reduced 26.83%	389,496 $24.6 Million
Q1 2023 May 15, 2023	BUY	$37.97 - $50.0 $2.54 Million - $3.34 Million	66,798 Added 14.35%	532,327 $23.9 Million
Q4 2022 Feb 14, 2023	SELL	$41.06 - $66.48 $44.1 Million - $71.4 Million	-1,074,179 Reduced 69.77%	465,529 $20.4 Million
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $6.05 Million - $9.41 Million	-121,084 Reduced 7.29%	1,539,708 $101 Million
Q2 2022 Oct 27, 2022	BUY	$45.23 - $70.15 $65 Million - $101 Million	1,436,317 Added 639.86%	1,660,792 $83.9 Million
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $65 Million - $101 Million	1,436,317 Added 639.86%	1,660,792 $83.9 Million
Q1 2022 Oct 27, 2022	SELL	$54.1 - $110.08 $77.7 Million - $158 Million	-1,436,317 Reduced 86.48%	224,475 $14.3 Million
Q1 2022 May 13, 2022	BUY	$54.1 - $110.08 $4.61 Million - $9.39 Million	85,298 Added 61.29%	224,475 $14.3 Million
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $404,709 - $498,061	4,294 Added 3.18%	139,177 $14.9 Million
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $10.9 Million - $14.8 Million	134,883 New	134,883 $13.9 Million

Others Institutions Holding BPMC

# of Institutions

389

Shares Held

66.9M

Call Options Held

973K

Put Options Held

1.54M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.73B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account